The letter claims the city wants to offer Keystone Group 'fair market value' for the roughly 19 remaining acres.
LEBANON, Ind. — Eli Lilly and Company announced it has more than doubled its investment in itsThe new $5.3 billion commitment increases the company's total investment in the site from $3.7 billion to $9 billion.
The expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients for Zepbound and Mounjaro injections so more adults with chronic diseases like obesity and type 2 diabetes can benefit from these treatments. "Lilly continues to play a transformational role in shaping Indiana's opportunity economy, and I couldn't be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been driving global innovation and economic growth that will be felt for decades here at home," Indiana Gov. Eric Holcomb said.
The additional investment in the Lebanon site, which is located within Indiana's LEAP Research and Innovation District, will add 200 full-time jobs for workers such as engineers, scientists, operating personnel and lab technicians. The facility will have an estimated 900 full-time employees when it's fully operational.Credit: WTHR/Matthew Fultz
Indiana leaders announced Eli Lilly and Company more than doubled its investment in its Lebanon manufacturing site.The company expects to begin making medicines in Lebanon toward the end of 2026, with operations scaling up through 2028.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Read more »
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Read more »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit. The drugmaker also hiked its forecast for 2024 well beyond analyst expectations after sales of Mounjaro more than tripled in the year’s first quarter.
Read more »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit.
Read more »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit.
Read more »
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issuesRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit
Read more »